NVCRNovoCure GmbHRunning, no new patients
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Glioblastoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
8 insiders sold shares within a month
Since Jun 4, 2026 · was worth 10, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 741 (planned)
- Started
- Feb 3, 2025
- Main results expected
- Apr 2029
- Fully finished
- Apr 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall survival
Measured over: 24 months
Changes Tremor has spotted
Status changed: Signing up patients → Running, no new patients. Usually normal progress.
Spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.7, since 2026-06-04, fades (half-life)
Raw record changes
- 2026-11-06 15:29 UTC · status_changed · overall_status
old: "RECRUITING"
new: "ACTIVE_NOT_RECRUITING"
Trial ID NCT06556563 · record last updated 2026-11-06 · checked 2026-11-09 15:36 UTC